ArticleJournal of Korean medical science2026
Effect of Metformin in Diabetic Patients After Treatment of Intracranial Aneurysm: A Nationwide Cohort Study.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIntracranial aneurysm (IA) is the most common cause of subarachnoid hemorrhage (SAH), causing high morbidity and mortality. Experimental data have shown that metformin, an antidiabetic agent, has protective effects against IA rupture. This study assessed the effect of metformin on the long-term prognosis of diabetic patients treated for IA.
methodsThis retrospective cohort study included diabetic patients who underwent surgical clipping or endovascular coiling for IA between January 2009 and December 2020, based on Korean health insurance claims data. The primary outcome was the development of SAH. The risk associated with metformin use was evaluated using a multivariable Cox proportional hazards model supplemented with subgroup, propensity score matching, and time-varying Cox regression analyses.
resultsOf 14,086 diabetic patients treated for IA, 9,612 (68.2%) were metformin users. During a mean follow-up of 4.6 years, 120 (0.9%) patients experienced SAH. Metformin use was associated with a reduced risk of SAH (adjusted hazards ratio, 0.63; 95% confidence interval, 0.41-0.95;
conclusionMetformin use in diabetic patients treated with clipping or coiling for IA was associated with reduced risk of SAH. These findings support the use of metformin as the preferred antidiabetic agent for such patients considering these benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.